Urinary enzyme excretion during treatment of malignancies with human recombinant alpha-2 interferon.
D000118:Acetylglucosaminidase / Q000652:urine*; D000328:Adult; D005260:Female; D005696:Galactosidases / Q000652:urine*; D006596:Hexosaminidases / Q000652:urine*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use* / Q000633:toxicity; D007668:Kidney / Q000187:drug effects; D007770:L-Lactate Dehydrogenase / Q000652:urine*; D007931:Leucyl Aminopeptidase / Q000652:urine*; D007951:Leukemia, Myeloid / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008297:Male; D009369:Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D001616:beta-Galactosidase / Q000652:urine*; D005723:gamma-Glutamyltransferase / Q000652:urine*
D007370:Interferon Type I; D011994:Recombinant Proteins; D007770:L-Lactate Dehydrogenase; D005723:gamma-Glutamyltransferase; D005696:Galactosidases; D006596:Hexosaminidases; D001616:beta-Galactosidase; D000118:Acetylglucosaminidase; D007931:Leucyl Aminopeptidase